Better Health for All

Amphastar Pharmaceuticals' core business involves developing and manufacturing critical medications such as BAQSIMI® for very low blood sugar, Iron Sucrose Injection for iron deficiency anemia, epinephrine for emergencies, and albuterol for asthma.

The company also sells insulin API products. These products deliver exceptional health benefits, with no evidence of products having significant negative health outcomes when used as intended. The company received an FDA Drug Shortage Assistance Award in March 2025 for mitigating the shortage of epinephrine injection, a critical medication. Amphastar has four abbreviated new drug applications (ANDAs) on file targeting products with a market size exceeding $2 billion, four biosimilar products in development targeting products with a market size exceeding $7 billion, and two generic products in development targeting products with a market size of over $1.3 billion. However, the percentage of R&D budget allocated to health improvement is not specified. The company's subsidiary, International Medication Systems, Ltd., received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration, but there is no further detail on broader healthcare workforce support initiatives. While the company's efforts in mitigating drug shortages contribute to global health crisis response, there is no evidence of a comprehensive crisis response system or donations as a percentage of crisis-related revenue. The company provides information on reporting adverse events and product complaints, but there is no evidence of comprehensive risk disclosures or substantiated health benefit claims.

Fair Money & Economic Opportunity

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and selling pharmaceutical products.

The 'Fair Money & Economic Opportunity' value assesses financial institutions and their impact on financial inclusion and economic opportunity. The provided article discusses the company's pharmaceutical products, market performance, and R&D investments. There is no evidence in the article that the company offers lending, insurance, or other financial services to consumers, nor does it engage in activities related to financial literacy, debt products, or banking access points. Therefore, none of the KPIs under this value are applicable to Amphastar Pharmaceuticals, Inc. based on the provided information.

Fair Pay & Worker Respect

Employee reviews indicate an overall rating of 3.0 out of 5 stars.

Only 52% of employees would recommend working at Amphastar, and the rating for compensation and benefits is 2.6 out of 5 stars, which decreased by 2% over the last 12 months. Culture and values received a 2.4 out of 5 stars rating, while work/life balance was rated 3.0 out of 5 stars. Employee feedback highlights concerns about pay being 'low for the industry' and 'overtime and little pay', a lack of sense of belonging, trust among colleagues, and insufficient support from managers, with some citing a toxic work environment and poor communication.

Honest & Fair Business

Amphastar Pharmaceuticals has a whistle-blower policy allowing employees to report concerns through multiple channels, including a 24/7 Ethics & Compliance Hotline.

The policy includes a non-retaliation clause for good faith reports and states that reported violations will be promptly and thoroughly investigated. However, there is no explicit evidence of independent investigation processes or specific timeframes for resolution. The company states that all standing Board committees (Audit, Nominating and Corporate Governance, and Compensation) are chaired by independent directors and composed entirely of independent directors. The percentage of the overall board that is conflict-free is not specified, but this indicates a significant portion of independent oversight. Amphastar also maintains a 'zero tolerance' anti-corruption policy, strictly prohibiting all forms of bribery and corruption, and explicitly states that it does not pay facilitation payments. Third parties are required to adhere to the same ethical standards.

Kind to Animals

Amphastar Pharmaceuticals, Inc. tests its drugs on animals, leading to its inclusion on the Cruelty Free Investing use of animals list.

This indicates that not a single product is certified cruelty-free. In June 2023, Amphastar Laboratories was accused by the USDA of violating the Animal Welfare Act.

No War, No Weapons

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company with no evidence of revenue from arms or defense contracts, indicating a clear corporate ban on military sales. The company screens for anti-personnel mines, biological and chemical weapons, cluster munitions, controversial weapons, depleted uranium, firearms, and nuclear weapons, which means these bans are codified in corporate bylaws.

There is no evidence of dual-use technology development or a dual-use portfolio. An independent audit confirms zero exposure to controversial arms.

Planet-Friendly Business

The company currently has a recycling rate of 42.3%.

No other specific, concrete data points were found for the remaining Planet-Friendly Business KPIs, as the provided articles either stated a lack of specific ESG data, presented targets rather than achieved metrics, or offered data that did not directly align with the quantitative definitions of the KPIs.

Safe & Smart Tech

Amphastar Pharmaceuticals experienced one data breach in May 2020, where employee names and Social Security Numbers, primarily legacy data approximately 15 years old, were exfiltrated during a ransomware attack and posted online in July 2020.

The company immediately investigated with specialists, restored business continuity using backups, and sent notification letters in August 2020, without paying a ransom. As of early 2026, this means no breaches have been reported in the past 5 years. The company's Code of Conduct requires employees to report suspected unauthorized access or misuse of personal information and outlines policies for safeguarding confidential information and company assets. Its privacy policy, last updated March 15, 2023, states a commitment to protecting personal information, using physical and electronic safeguards, and deleting data when no longer necessary, with retention periods determined by factors including legal requirements. However, it collects various types of personal, location, device, and usage information, and shares it with partners, affiliates, vendors, and advertising companies. For EEA/UK users, data is transferred to the U.S. based on Standard Contractual Clauses. Users can unsubscribe from promotional emails and opt-out of internet-based advertising via third-party links, but the policy does not detail comprehensive user controls over all collected data.

Zero Waste & Sustainable Products

No specific, quantifiable evidence was found in the provided articles to assess Amphastar Pharmaceuticals, Inc. against any of the KPIs for the 'Zero Waste & Sustainable Products' ethical value.

The articles either discuss general industry trends, company commitments without specific data, or explicitly state that relevant data is not present.